Europe Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Europe Next-Generation Sequencing (NGS) Services Market was valued at $324.6 Million in 2017 and projected to reach to $820.4 Million by 2022, representing a compound annual growth rate of CAGR 20.4%. Europe's NGS Services Market is positioned for continued expansion through 2022 and beyond, driven by increasing clinical adoption, growing demand for precision medicine, and substantial investments in genomic research initiatives.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe Next-Generation Sequencing (NGS) Services Market Trends and Insights
- This expansion reflects Europe's increasing adoption of advanced genomic technologies across clinical diagnostics, research institutions, and pharmaceutical development.
- Europe's strong healthcare infrastructure, coupled with rising investments in precision medicine and genomic research initiatives, has positioned the region as a key driver of NGS service adoption. The 20.4% compound annual growth rate (CAGR) observed in Europe underscores the region's commitment to integrating NGS into mainstream healthcare delivery and life sciences research.
- Europe's regulatory frameworks, collaborative research networks, and emphasis on personalized medicine have accelerated the deployment of NGS services across oncology, rare disease diagnosis, and pharmacogenomics applications.
- The forecast period through 2022 reflects Europe's sustained momentum in genomic innovation and clinical implementation. Europe's NGS market growth is supported by increasing healthcare expenditure, growing awareness of genomic medicine benefits, and expanding laboratory capabilities across the continent.
- The region's diverse healthcare systems and research ecosystems continue to drive demand for comprehensive NGS service offerings..
Key Market Statistics
- CAGR (2017-2022) CAGR 20.4%
- Market Size, 2017 ~USD 324.6 Million
- Forecast, 2022 ~USD 820.4 Million
- Geography Europe
Europe Next-Generation Sequencing (NGS) Services Market Overview
Strong Market Expansion :
Europe's NGS Services Market grew from $324.6 million in 2017 to $820.4 million by 2022, representing a 20.4% CAGR and demonstrating sustained investment in genomic sequencing infrastructure across the region.
Clinical Diagnostics Leadership :
European healthcare systems are increasingly integrating NGS into clinical diagnostics for cancer genomics, rare disease identification, and personalized medicine, driving adoption across major medical centers and diagnostic laboratories.
Research & Pharma Investment :
Europe's robust pharmaceutical and academic research sectors are leveraging NGS services for drug discovery, biomarker development, and clinical trials, supported by strong regulatory frameworks and funding initiatives.
Advanced Healthcare Infrastructure :
Europe's well-established healthcare infrastructure, coupled with high healthcare spending and favorable reimbursement policies, creates an optimal environment for NGS service adoption and market growth.
Europe Next-Generation Sequencing (NGS) Services Market Dynamics
- The region's mature healthcare systems and strong regulatory support create favorable conditions for service providers and technology innovators.
- Germany and the U.K.
- lead market growth, while emerging adoption in France and Rest of Europe presents significant expansion opportunities.
- Consolidation among service providers and integration of AI-driven analytics are expected to enhance service offerings and market competitiveness..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Europe's NGS Services Market grew from $324.6M (2017) to $820.4M (2022), representing a 20.4% CAGR.
- Europe's strong healthcare infrastructure and precision medicine initiatives drive sustained NGS adoption across clinical and research settings.
- Europe's regulatory environment and collaborative research networks accelerate integration of NGS into oncology, rare disease diagnosis, and pharmacogenomics.
- Europe's diverse healthcare systems and expanding laboratory capabilities position the region for continued NGS service market expansion.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Europe Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
EUROPE: NEXT-GENERATION SEQUENCING SERVICES MARKET, BY END USER, 2015–2022
| Segment | 2015 | 2016 | 2017 | 2022 | CAGR (%) |
|---|---|---|---|---|---|
| ACADEMIC & GOVERNMENT INSTITUTES AND RESEARCH CENTERS | 123.8 | 154.7 | 189.5 | 500.7 | 21.5 |
| HOSPITALS & CLINICS | 47.9 | 58.1 | 69.1 | 156.9 | 17.8 |
| OTHER END USERS | 13.8 | 17.1 | 20.8 | 53 | 20.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 30.4 | 37.4 | 45.1 | 109.8 | 19.5 |
| TOTAL | 215.9 | 267.4 | 324.6 | 820.4 | 20.4 |
Target Audience
- NGS Service Providers : Service companies need European market intelligence to optimize service offerings, identify growth markets, understand competitive positioning, and develop region-specific go-to-market strategies.
- Pharmaceutical & Biotech Companies : Drug developers require insights into European NGS adoption trends, clinical validation pathways, and service provider capabilities to support drug discovery and clinical trial strategies.
- Healthcare Systems & Hospitals : European medical institutions need market data to evaluate NGS service integration, benchmark adoption rates, assess provider options, and plan genomic medicine program investments.
- Diagnostic Laboratory Operators : Laboratory networks require competitive intelligence on European NGS market dynamics, service pricing, technology trends, and clinical demand forecasts to guide expansion and technology investments.
- Healthcare Investors & Consultants : Investment firms and management consultants need comprehensive European NGS market analysis to identify acquisition targets, assess market opportunities, and guide portfolio company strategies.
Key Companies in the Europe Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 290.7 Million |
| U.K. | USD 226.4 Million |
| France | USD 151.1 Million |
| Roe | USD 152.1 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Detailed breakdown of NGS market performance across Germany, U.K., France, and Rest of Europe, enabling targeted market entry and expansion strategies specific to European sub-regions.
- Clinical Adoption Insights : Comprehensive analysis of NGS integration in European clinical diagnostics, oncology, and rare disease detection, helping stakeholders understand adoption drivers and clinical implementation trends.
- Competitive Landscape Analysis : Identification of leading NGS service providers, technology platforms, and competitive positioning within Europe, supporting strategic partnerships and market differentiation planning.
- Regulatory & Reimbursement Framework : In-depth examination of European regulatory requirements, reimbursement policies, and healthcare system dynamics that influence NGS service adoption and pricing strategies.
- Growth Forecasting & Opportunity Assessment : Detailed 2022 market forecasts and CAGR projections for Europe, identifying high-growth segments, emerging opportunities, and investment priorities for service expansion.
Frequently asked questions
What was Europe's NGS Services Market size in 2017?
Europe's NGS Services Market was valued at $324.6 million in 2017.
What is the projected size of Europe's NGS Services Market by 2022?
Europe's NGS Services Market is forecasted to reach $820.4 million by 2022.
What is the CAGR for Europe's NGS Services Market?
Europe's NGS Services Market is projected to grow at a compound annual growth rate (CAGR) of 20.4% from 2017 to 2022.
What factors are driving NGS adoption in Europe?
Europe's NGS adoption is driven by strong healthcare infrastructure, precision medicine initiatives, regulatory support, collaborative research networks, and expanding laboratory capabilities across the continent.
Which applications are leading NGS service demand in Europe?
Europe's NGS service demand is led by oncology diagnostics, rare disease diagnosis, pharmacogenomics, and clinical research applications across diverse healthcare systems.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
